Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
企業コードVALN
会社名Valneva SE
上場日Jun 28, 2007
設立日1999
最高経営責任者「CEO」Mr. Thomas Lingelbach
従業員数- -
証券種類Depository Receipt
決算期末Jun 28
本社所在地6 rue Alain Bombard
都市SAINT-HERBLAIN
証券取引所NASDAQ Global Select Consolidated
国France
郵便番号44800
電話番号33228073710
ウェブサイトhttps://valneva.com/
企業コードVALN
上場日Jun 28, 2007
設立日1999
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし